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Abstract Telomere length is maintained by the ribonucleopro-
tein enzyme telomerase. The RNA component of telomerase
(hTR) is widespread, and only the expression of the mRNA
encoding the catalytic protein subunit (hTRT) is correlated with
telomerase activity. We have studied the level of expression of
hTR and hTRT in four different models of neoplastic and
preneoplastic lesions using the RT-PCR method on RNA
extracted from paraffin-embedded human tissues after micro-
dissection. The expression at the mRNA level was compared with
the enzymatic activity. Our results suggest that there may be a
reciprocal control at the transcriptional level of the expression of
hTRT and hTR which in turn is associated with tumor
progression.
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1. Introduction
Telomerase is a ribonucleoprotein detected in immortalized
cells and in most tumors studied [1]. Its activity seems to be
associated with tumor progression, but it is also possible to
¢nd telomerase-positive cells in normally regenerating human
tissues [2]. These facts suggest that telomerase is connected
with proliferation and plays a permissive rather than an ini-
tiating role in cancer.
The control of telomerase expression and activity is still
unclear. There are many suggestions that could explain this
control, such as alternative splicing of the enzyme gene tran-
scripts [3] or relationship with the expression of retinoblasto-
ma or myc genes [4^6]. Another possible control could be
connected directly with the ribonucleoprotein components.
The relationship between the cellular levels of the compo-
nents of the ribonucleoprotein is not clear. The RNA compo-
nent presents a widespread expression [7,8], whilst the cata-
lytic component shows a restricted pattern of expression,
related to the enzyme activity [9]. A multistage tumorigenesis
study in transgenic mice has shown that the RNA component
of telomerase is up-regulated in the ¢rst stages of tumorigen-
esis, even in precancerous lesions, but the telomerase enzy-
matic activity is detectable only in the later stages of tumor
progression [10]. This fact suggests that a down-regulation of
the RNA component of the ribonucleoprotein is present only
at the appearance of the enzymatic activity.
The RNA component (hTR) and the catalytic component
(hTRT) of human telomerase have been sequenced [7,9] and
we have analyzed their expression at the RNA level in human
tumors and precancerous lesions using RNA extracted from
para⁄n-embedded tissues. The aim of this study was to show
in human models the association between the expression of
the telomerase RNA component and the protein catalytic
component.
2. Materials and methods
2.1. Tissues
Fresh surgical homogeneous tissues fragments were divided into
two parts. One half was para⁄n-embedded for RT-PCR analysis
and the other was frozen and stored at 380‡C for the telomeric repeat
ampli¢cation protocol (TRAP) assay. We collected 10 samples: three
hyperplastic lymph nodes, two lymph nodes with metastases, a meta-
static lymph node with extensive necrosis, two breast carcinomas, a
breast cancer local recurrence and a urinary bladder wall with severe
neutrophil in¢ltration and edema. Frozen tissues were powdered in
liquid nitrogen. Total RNA from para⁄n-embedded human tissues
with cancer of liver, brain and breast was extracted as already re-
ported [11] or using Total Quik RNA (Talent, Italy). The use of
para⁄n-embedded tissues allowed a correct identi¢cation and local-
ization of the lesions; the tissues were microdissected and only the
selected cells were subjected to RNA extraction. We analyzed 14 cases
of primary carcinoma of the liver and 16 cases of glioma of the brain.
RNA was also extracted from 28 breast carcinomas and 18 cases of
precancerous (CIN2) and nine cases of in situ carcinomas of the cervix
uteri.
2.2. Northern analyses
Northern blot analyses were carried out on total RNA extracted
from HeLa cells as a positive control, a renal tumor, a breast cancer
and a mammary tissue. Northern blot analysis and probe preparation
were carried out according to standard methods [12]. Total RNA for
each sample (10 Wg) was fractionated on a 1% formaldehyde agarose
gel and blotted on a positively charged nylon membrane. The mem-
branes were tested with 32P-labeled hTR and hTRT amplicons (using
the oligonucleotides reported in Section 2.4) puri¢ed from low-melting
agarose gel. For the same specimens also RT-PCR for hTR and
hTRT and TRAP assay on protein lysates was performed.
2.3. Trap assay
Extracts of tissue proteins were obtained incubating the powder in
ice-cold lysis bu¡er (10 mM Tris-HCl pH 7.5, 1 mM MgCl2, 1 mM
EGTA, 0.1 mM phenylmethylsulfonyl £uoride, 5 mM L-mercapto-
ethanol, 0.5% CHAPS, 10% glycerol) for 30 min. Telomerase activity
was assayed by a modi¢ed TRAP method to avoid direct primers
interactions [13], using 10 Wg of protein lysate for each sample. The
PCR products were analyzed on a 15% non-denaturing polyacryl-
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 3 5 7 - 5
*Corresponding author. Fax: (39) (40) 226 555.
E-mail: stanta@icgeb.trieste.it
Abbreviations: hTR, RNA component of human telomerase; hTRT,
mRNA of the catalytic subunit of human telomerase; RT-PCR, re-
verse transcription PCR; TRAP, telomeric repeat ampli¢cation pro-
tocol; CIN, cervix intraepithelial neoplasia
FEBS 22794 19-10-99
FEBS 22794 FEBS Letters 460 (1999) 285^288
amide gel. The level of radioactivity of each lane of the gel was
measured using a computerized phospho imaging system (Istant Im-
ager, Packard Instrument Company).
2.4. RNA analysis
For the hTR and hTRT analysis a DNase digestion of RNA was
performed to avoid genomic DNA contamination. For RT-PCR anal-
ysis were used speci¢c oligonucleotides [7] (hTR1: 5P-TAGGC-
GCCGTGCTTTTGCT-3P ; hTR3: 5P-GCTCTAGAATGAACG-
GTG-3P) with the ampli¢cation of a 99 base fragment for the RNA
component and for the catalytic component of the telomerase [9]
(hTRT1: 5P-AGCCAGTCTCACCTTCAA-3P ; hTRT3: 5P- ACAGG-
CTGTGACACTTCA-3P). For hTRT the amplicon was 92 bases long.
The dot blot of the ampli¢ed material was hybridized with an internal
probe (hTR2: 5P-CGCTGTTTTTCTCGCTGACTTTCAGCG-3P) for
RNA component and (hTRT2: 5P-GGAACATGCGTCGCAAA-
CTCTTTG-3P) for mRNA of the catalytic component. The results
were analyzed by a computerized phosphor imaging system. Relative
quanti¢cation of the speci¢c RNA was performed, after standardiza-
tion of the RNA degradation level on the L-actin expression levels,
with initial RNA quantity and ampli¢cation conditions consistent
with a linear relationship between the log of the target RNA and
the log of the ampli¢ed product [14,15]. These conditions were satis-
¢ed with 45 ng of total RNA per test and with ¢ve cycles of ampli-
¢cation of 95‡C/1 min, 55‡C/1 min, 72‡C/1 min and 40 cycles of 95‡C/
30 s, 55‡C/30 s and 72‡C/30 s for the RNA component. For the
catalytic component the conditions were 250 ng of total RNA and
¢ve cycles of ampli¢cation of 95‡C/1 min, 55‡C/1 min, 72‡C/1 min
and 30 cycles of 95‡C/30 s, 55‡C/30 s and 72‡C/30 s.
3. Results and discussion
The limited amount of RNA of reasonable molecular
weight that can be obtained from para⁄n-embedded tissue
sample makes RT-PCR the only methodology capable of
measuring hTR and hTRT mRNA. To validate this technique
and establish its correlation with enzymatic activity we com-
pared in three fresh human tissue specimens (a renal cancer, a
breast cancer and a normal mammary tissue) the RT-PCR-
based method with the TRAP assay and Northern blot. For
every one of the three specimens we found a positive qualita- tive correlation for both the telomerase components in North-
ern blot and RT-PCR with enzyme activity (Fig. 1).
To establish the quantitative relationship between methods,
telomerase activity was detected with TRAP analysis in fresh
tissues of 10 human tissues and the results were compared
with RT-PCR-based method in the same para⁄n-embedded
cases. We found a good quantitative correlation between ac-
tivity measured with TRAP and hTRT mRNA expression in
eight cases (r = 0.68). The other two cases, a lymph node with
Fig. 1. A: TRAP assay for telomerase activity (lanes 1, 2: positive
and negative control; lane 3: renal cancer; lane 4: mammary gland;
lane 5: breast carcinoma). B: Dot-blot relative of hTR expression
(negative control, positive control, renal tumor, breast carcinoma
and mammary gland). C: Dot-blot relative of hTRT expression
(negative and positive controls, renal tumor, mammary tissue and
breast carcinoma). D: Northern blot relative of hTR (positive con-
trol, renal tumor, breast cancer and mammary gland, negative con-
trol). E: Northern blot relative of hTRT (positive and negative con-
trols, renal tumor, breast carcinoma and mammary tissue).
Fig. 2. A: TRAP assay for telomerase activity (lanes 1, 2: positive
and negative control; lanes 3, 5: lymph nodes with metastasis; lanes
4, 11, 12: hyperplastic lymph nodes; lane 6: lymph node with ne-
crotic metastasis; lane 7: breast carcinoma; lane 8: urinary bladder
in£ammation; lane 9: breast carcinoma recurrence; lane 10: breast
carcinoma). B: Dot-blot relative of hTR expression (a1, a3: positive
controls; a2: negative control; a4, a5: lymph nodes with metastasis;
a6: lymph node with necrotic metastasis; a7: breast carcinoma; b1:
breast carcinoma recurrence; b2: urinary bladder in£ammation; b3:
breast carcinoma; b4, b5, b6: hyperplastic lymph nodes). C: Dot-
blot relative of hTRT expression (a1, b1: positive controls; a2, a3:
lymph nodes with metastasis; a4: lymph node with necrosis; a5:
breast carcinoma; b2: urinary bladder in£ammation; b3: breast car-
cinoma recurrence; b4: breast carcinoma; b5, c2, c3: hyperplastic
lymph nodes; c4: negative control).
Fig. 3. Relative standardized quantitation of hTR and hTRT
mRNA in brain tumors.
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a necrotic cancer metastasis and a urinary bladder wall with
severe neutrophil in¢ltration, were positive for hTRT mRNA
expression but negative or with a very low activity with TRAP
analysis. In both cases necrosis and severe neutrophil in¢ltra-
tion led to proteolysis and protein degradation that a¡ected
the TRAP assay (Fig. 2). No quantitative correlation was
found between the enzyme activity and the expression of the
RNA component of telomerase.
We studied the telomerase RNA component (hTR) and the
mRNA of the catalytic component (hTRT mRNA) in four
types of human cancer. The expression of hTR and the level
of the hTRT mRNA were compared in brain, liver, and breast
cancers, and in cervix uteri precancerous lesions.
In gliomas of the brain the level of expression of hTR
appears unrelated to the hTRT mRNA for lower levels of
expression of the latter (Fig. 3). When the catalytic subunit
mRNA presented higher expression we found a good linear
correlation between the two components (r = 0.86). The sec-
ond model, the liver hepatocarcinomas, showed a similar pat-
tern (Fig. 4A) with no correlation at lower levels of protein
mRNA and a linear relationship with the RNA component at
higher levels of protein expression (r = 0.88). The same behav-
ior as the previous two models was found in breast carcino-
mas (r = 0.75) (Fig. 4B). There was a linear relationship be-
tween hTR and hTRT expression also for cervix uteri in situ
carcinomas (r = 0.90) (Fig. 4D), but in cervical precancerous
dysplasias there was no correlation between the two levels of
expression (Fig. 4C).
To study human tissues the availability of extensive ar-
chives of para⁄n-embedded tissues from biopsies and
autopsies is an invaluable resource that unfortunately was
not tapped until now for telomerase-tumor progression asso-
ciations. Obviously it is impossible to measure enzyme activity
in ¢xed tissues but we have developed a reliable RT-PCR
method to quantify the amounts of hTR and hTRT [14,15].
It was already stressed that the correlation between hTRT
mRNA and the level of telomerase activity remains to be
clari¢ed [16]. Our data suggest that there is a good quantita-
tive correlation between the activity and the expression of the
enzyme, with some limitations due mostly to proteolysis proc-
esses that can a¡ect the TRAP analysis. In the two cases in
which activity could not be shown, there were cellular proc-
esses that could be ascribed to protein degeneration and lysis,
i.e. necrosis and neutrophil in¢ltration. A signi¢cant correla-
tion between hTRT expression and telomerase activity has
already been reported in the literature [17].
In this study we analyzed the presence of the telomerase
RNA component (hTR) and its relationship with the catalytic
component (hTRT) expression in four di¡erent groups of hu-
man tumors. Once the correlation between hTRT mRNA
levels and telomerase activity was established, it was possible
to focus on the relationship that exists between the RNA and
the catalytic components of the ribonucleoprotein in para⁄n-
embedded tissues, which does not allow the detection of telo-
merase activity, but has the advantage of the sure recognition
and collection of the lesions, which can then be easily micro-
dissected with the analysis con¢ned to the cells involved. It
was recently reported that in many tumors previously scored
as telomerase negative, the activity was detected after careful
histological con¢rmation with an adjacent cryosection of the
lesions and microdissection [18].
Our data indicated that in four di¡erent neoplastic models a
relationship exists between the structural RNA and the
mRNA encoding the catalytic component of telomerase.
When the mRNA of the catalytic subunit reaches a certain
level of expression the RNA component is linearly correlated.
Fig. 4. Relative standardized quantitation of hTR and hTRT-mRNA in breast carcinomas (A), liver tumors (B), cervix uteri precancerous dys-
plasias (C) and cervix uteri in situ carcinomas (D).
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This correlation is absent for low or absent expression of the
protein component. The meaning of this high expression of
the RNA component in cases without an evident protein com-
ponent expression must be further investigated. The simplest
explanation for this di¡erent relationship between the two
components of telomerase could be ascribed to a di¡erent
proportion of cycling cells in tissues. It was recently shown
in preneoplastic and neoplastic early lesions that the amount
of hTRT mRNA present within individual cells increased
gradually during progression and also the number of express-
ing cells increased within the same tumor [15]. It was also
suggested that the level of activity of telomerase could corre-
spond to the percentage of primarily immortal or mortal can-
cer cells within the tissues [19]. That telomerase activity is
connected with the continuous progression of the tumor is
shown by the fact that telomerase reactivation occurs during
progression in multistep human colorectal carcinogenesis [20].
On the other hand, the level of expression of the RNA com-
ponent of the ribonucleoprotein seems to be unrelated to the
activity of the enzyme. In lung precancerous lesion the expres-
sion of hTR was not directly connected to the telomerase
activity and highly expressed from in situ non-in¢ltrative tu-
mors with low enzyme activity [21]. The same discrepancy was
noted in multistage tumorigenesis in transgenic mice in which
the up-regulated RNA component did not parallel the amount
of telomerase activity detected in precancerous cells [10]. Also
in the mouse the telomerase RNA component is up-regulated
in early hyperproliferative stages of tumor progression before
telomerase activity is apparent [22]. The cervix uteri model
con¢rms these data and gives a clearer picture that there is
no relationship between RNA and protein component of te-
lomerase in precancerous lesions. A good linear relationship
was instead found for in situ carcinomas (Fig. 4). A stoichio-
metric ratio of the two component of the ribonucleoprotein
telomerase is probably reached only in the ¢rst step of a true
cancer lesion but not in the precancerous one.
It is known that the telomerase catalytic subunit binds the
structural RNA and this complex interacts with the telomeres.
This RNA-protein interaction may not be only a catalytic
subunit-template interaction but could be also a regulatory
loop. There are systems where regulation is achieved by bind-
ing of RNA to a transcription factor. Transcription factor
IIIA binds to 5S RNA to regulate its synthesis [23], another
example is reported for HIV in which TAT protein transacti-
vation is achieved by binding an RNA sequence [24]. The
changes observed in hTR RNA and in hTRT mRNA levels
would be consistent with a regulation of telomerase RNA
synthesis by the level of the telomerase catalytic subunit
present.
Ho¡man and collaborators found in kidney fetal tissues
alternative splicing of hTRT transcripts as a mechanism con-
trolling the telomerase activity [3], others found a possible
transcriptional control connected with the expression of reti-
noblastoma protein and the myc gene [4^6]. Some authors
have shown inhibition of telomerase activity by treating cells
with 9-hydroxyellipticine (an antitumor alkaloid) irrespective
of p53 status [25]. We suggest there is another possible tran-
scriptional control, a cross-regulation between the RNA and
catalytic components of telomerase. High expression of hTR
could down-regulate the expression of the protein component,
when enough hTRT is expressed to form a stoichiometric
complex with the RNA component, then the relationship
hTR/hTRT levels will tend to be linear.
The suggestion of these regulatory loops between the two
components of telomerase could contribute to explain the role
of this enzyme in tumor progression.
References
[1] Kim, N.W., Piatyszek, A.M., Prowse, K.R., Harley, C.B., West,
M.D., Ho, L.C., Coviello, G.M., Wright, W.E., Weinrich, S.L.
and Shay, J.W. (1994) Science 266, 2011^2015.
[2] Yasumoto, S., Kunimura, C., Kikuchi, K., Tahara, H., Ohji, H.,
Yamamoto, H., Ide, T. and Utakoji, T. (1996) Oncogene 13,
433^439.
[3] Ulaner, G.A., Hu, J.F., Vu, T.H., Giudice, L.C. and Ho¡man,
A.R. (1998) Cancer Res. 58, 4168^4172.
[4] Xu, H.J., Zhou, Y., Ji, W., Perng, G.S., Kruzelock, R., Kong,
C.T., Bast, R.C., Mills, G.B., Li, J. and Hu, S.X. (1997) Onco-
gene 15, 2589^2596.
[5] Wang, J., Xie, L.Y., Allan, S., Beach, D. and Hannon, G.J.
(1998) Genes Dev. 12, 1769^1774.
[6] Horikawa, I., Cable, P.L.A., Afshari, C. and Barrett, J.C. (1999)
Cancer Res. 59, 826^830.
[7] Feng, J., Funk, W.D., Wang, S.S. and Villeponteau, B. (1995)
Science 269, 1236^1241.
[8] Avilion, A.A., Piatyszek, M.A., Gupta, J., Shay, J.W., Bacchetti,
S. and Greider, C.W. (1996) Cancer Res. 56, 645^650.
[9] Meyerson, M., Counter, C.M. and Eaton, E.N. et al. (1997) Cell
90, 785^795.
[10] Blasco, A.M., Rizen, M., Greider, C.W. and Hanahan, D. (1996)
Nature Genet. 12, 200^204.
[11] Stanta, G., Bonin, S. and Perin, R. (1998) In: Methods in Mo-
lecular Biology. RNA Isolation and Characterization Protocols
(Rapley, R. and Manning, D.L., Eds.), Vol. 86, pp. 23^26, Hu-
mana Press, Totowa, NJ.
[12] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY.
[13] Falchetti, M.L., Levi, A., Molinari, P., Verna, R. and D’Ambro-
sio, E. (1998) Nucleic Acids Res. 26, 862^863.
[14] Stanta, G., Bonin, S. and Utrera, R. (1998) In: Methods in
Molecular Biology. RNA Isolation and Characterization Proto-
cols (Rapley, R. and Manning, D.L., Eds.), Vol. 86, pp. 113^119,
Humana Press, Totowa, NJ.
[15] Stanta, G. and Bonin, S. (1998) BioTechniques 24, 271^276.
[16] Kolquist, K.A., Ellisen, L.W., Counter, C.M., Meyerson, M.,
Tan, L.K., Weinderberg, R.A., Harber, D.A. and Gerald, W.L.
(1998) Nature Genet. 19, 182^186.
[17] Nakayama, J., Tahara, H., Tahara, E., Saito, M., Ito, K., Na-
kamura, H., Nakanishi, T., Tahara, E., Ide, T. and Ishikawa, F.
(1998) Nature Genet. 18, 65^68.
[18] Carey, L.A., Hedican, C.A., Henderson, G.S., Umbricht, C.B.,
Dome, J.S., Varon, D. and Sukumar, S. (1998) Clin. Cancer Res.
4, 435^440.
[19] Hiyama, K., Hiyama, E., Ishioka, S., Yamakido, M., Inai, K.,
Gazdar, A.F., Piatyaszek, M.A. and Shay, J.W. (1995) J. Natl.
Cancer Inst. 87, 895^902.
[20] Tang, R., Cheng, A.J., Wang, J.Y. and Wang, T.C.V. (1998)
Cancer Res. 58, 4052^4054.
[21] Yashima, K., Litzky, L.A., Kaiser, L., Rogers, T., Lam, S., Wis-
tuba, I.I., Milchgrub, S., Srivastava, S., Piatyaszek, M.A., Shay,
J.W. and Gazdar, A.F. (1997) Cancer Res. 57, 2373^2377.
[22] Broccoli, D., Godley, L.A., Donehower, L.A., Varmus, H.E. and
de Lange, T. (1996) Mol. Cell. Biol. 16, 3765^3772.
[23] Darsillo, P. and Huber, P.W. (1991) J. Biol. Chem. 266, 21075^
21082.
[24] Jones, K.A. (1994) Annu. Rev. Biochem. 63, 717^743.
[25] Sato, N., Mizumoto, K., Niiyama, H., Maehara, N., Ogawa, T.
and Tanaka, M. (1998) FEBS Lett. 441, 318^321.
FEBS 22794 19-10-99
G. Stanta et al./FEBS Letters 460 (1999) 285^288288
